7-Hydroxymitragynine
| Clinical data | |
|---|---|
| Other names | 7-OH; 7-OH-MIT; 7α-Hydroxy-7H-mitragynine; 9-Methoxycorynantheidine hydroxyindolenine |
| Dependence liability | High |
| Addiction liability | High |
| Routes of administration | Oral |
| Drug class | Opioid |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolites | Mitragynine pseudoindoxyl |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30N2O5 |
| Molar mass | 414.502 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
7-Hydroxymitragynine (7-OH-MIT), also commonly known simply as 7-OH, is a terpenoid indole alkaloid present in Mitragyna speciosa, the plant from which kratom is derived. It was first described in 1994. In humans, it is produced as an active metabolite of mitragynine via hepatic CYP450 enzymes.
7-OH-MIT exhibits greater binding affinity to μ-opioid receptors (MOR) than mitragynine. It acts primarily as a partial agonist at μ-opioid receptors while antagonizing δ- and κ-opioid receptors; unlike traditional opioids, it appears not to recruit the β-arrestin pathway, which may influence side effect profile. In animal studies, the compound has shown strong analgesic potency (reported MOR binding affinity up to ~13 times that of morphine) and produces opioid-like tolerance and withdrawal.
7-OH-MIT occurs only in very small amounts in natural kratom leaves (~2%), so most commercial material is produced semisynthetically through the oxone oxidation of kratom alkaloid extracts. Reports to poison control have risen substantially, and in 2025 the US Food and Drug Administration recommended that the compound be outlawed and moved into Schedule I.
It is being studied as a potential template for developing opioids with improved safety profiles.
- Drugs not assigned an ATC code